OS Therapies Raises $6M in Series A Funding

OS Therapies, a Cambridge, Md.-based clinical-stage biopharmaceutical company, closed a $6 million Series A round of funding.

Backers were not disclosed.

The company will use the funds to continue to advance its products.

Led by Dr. Robert Petit, CMO/CSO, and OS Therapies Executive Chair Colin Goddard, PhD, OS Therapies is a clinical stage therapeutic company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other deadly cancers in kids and adults.

The company’s lead product is OST-HER2 targeting Osteosarcoma in kids, which is a listeria cancer vaccine intended to prevent metastasis, increasing overall survival. 

The completed private placement will also support the advancement of preclinical and toxicology studies for OS Therapies’ second major platform technology OST-TDC: a next generation Drug Conjugate Technology targeting large solid tumors and potentially other diseases.